GlassScriptPhysician profile
Jazmin N Lowe
NPI 1265935589
$10,274.40
in general payments reported to CMS, 2019-2025
50 companies · $4,134 in 2025
The $4,134 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $43.00 · 2022: $496 · 2023: $1,360 · 2024: $4,242 · 2025: $4,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,477 · Long Term Medical Supply Or Device Loan: $1,446 · Education: $812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,477.45 |
| Long Term Medical Supply Or Device Loan | $1,446.39 |
| Education | $811.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,546.86 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $596.66 | 2022-2025 | Calquence, Enhertu, Tagrisso |
| Janssen Biotech, INC. | $577.02 | 2024-2025 | Darzalex, Tecvayli, Erleada |
| Celgene Corporation | $509.75 | 2024-2025 | Reblozyl, Pomalyst, Pomalyst |
| Seagen INC. | $504.31 | 2022-2025 | Tukysa, Adcetris |
| Incyte Corporation | $480.33 | 2023-2025 | Jakafi, Zynyz, Monjuvi |
| Pfizer INC. | $470.15 | 2023-2025 | |
| Lilly USA, LLC | $439.29 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| E.R. Squibb & Sons, L.L.C. | $407.29 | 2024-2025 | Opdivo, Krazati, Opdualag |
| Regeneron Healthcare Solutions, INC. | $363.42 | 2022-2025 | Libtayo |
| Daiichi Sankyo INC. | $340.38 | 2023-2025 | Enhertu, Injectafer, Datroway |
| Merck Sharp & Dohme LLC | $214.85 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Mirati Therapeutics, INC. | $209.86 | 2023-2024 | Krazati |
| Takeda Pharmaceuticals U.S.A., INC. | $201.93 | 2022-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Bayer Healthcare Pharmaceuticals INC. | $177.51 | 2023-2025 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $172.24 | 2023-2025 | |
| Astellas Pharma US INC | $170.50 | 2024-2025 | Vyloy, Padcev, Xospata |
| Array Biopharma INC | $156.05 | 2022-2025 | Braftovi, Lorbrena, Mektovi |
| Gilead Sciences, INC. | $151.76 | 2024-2025 | Trodelvy |
| Genentech USA, INC. | $149.95 | 2022-2025 | Itovebi, Tecentriq, Phesgo |
| Puma Biotechnology, INC. | $135.47 | 2023-2025 | |
| Eisai INC. | $129.75 | 2022-2025 | |
| Pharmacosmos Therapeutics INC. | $112.75 | 2025 | Monoferric |
| Glaxosmithkline, LLC. | $112.15 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Aveo Pharmaceuticals, INC. | $102.41 | 2024-2025 | |
| Exelixis INC. | $93.74 | 2024-2025 | Cabometyx |
| Alexion Pharmaceuticals, INC. | $78.65 | 2023-2024 | Ultomiris |
| Iovance Biotherapeutics, INC. | $61.21 | 2025 | Amtagvi |
| Amgen INC. | $58.92 | 2022-2023 | Lumakras |
| Tempus Ai, INC | $58.17 | 2024-2025 | Xt Cdx |
| Ipsen Biopharmaceuticals, INC | $56.88 | 2024 | Onivyde |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.29 | 2024 | Gilotrif |
| Emd Serono, INC. | $38.60 | 2024-2025 | |
| Sobi, INC | $33.83 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $33.41 | 2025 | |
| Deciphera Pharmaceuticals INC. | $28.11 | 2025 | Qinlock |
| Geron Corporation | $23.24 | 2025 | Rytelo |
| Genmab U.S., INC. | $21.96 | 2024 | Epkinly |
| Rigel Pharmaceuticals, INC. | $21.34 | 2023 | Rezlidhia, Tavalisse |
| Taiho Oncology, INC. | $20.97 | 2025 | |
| Jazz Pharmaceuticals INC. | $19.92 | 2025 | |
| Genzyme Corporation | $19.85 | 2024 | |
| Agios Pharmaceuticals, INC. | $19.79 | 2024 | |
| Apellis Pharmaceuticals, INC. | $17.89 | 2024 | Empaveli |
| Syndax Pharmaceuticals, INC. | $17.54 | 2025 | |
| Tersera Therapeutics LLC | $17.47 | 2024 | Xermelo |
| Blueprint Medicines Corporation | $16.66 | 2024 | Ayvakit |
| Nuvation Bio INC. | $16.41 | 2025 | Ibtrozi |
| Pharmacyclics LLC, An Abbvie Company | $13.78 | 2023 | Imbruvica |
| Beigene USA, INC. | $13.13 | 2024 | Brukinsa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jazmin Lowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.